Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil

What Was Tested

The paper reports a study of Cerebrolysin, published as a randomized controlled trial.

The researchers investigated the associations of six plasma NDEV markers with Alzheimer's disease (AD) severity, cognition and functioning, and changes in these biomarkers after Cerebrolysin®, donepezil, and a combination therapy in AD.

Why It Was Studied

Plasma neuronal-derived extracellular vesicles (NDEV) contain proteins of pathological, diagnostic, and therapeutic relevance.

Who Took Part

The abstract describes 20 subjects taking part.

Plasma NDEV levels of Aβ42, total tau, P-T181-tau, P-S393-tau, neurogranin, and REST were determined in: 1) 116 mild to advanced AD patients and in 20 control subjects; 2) 110 AD patients treated with Cerebrolysin®, donepezil, or combination therapy in a randomized clinical trial (RCT).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Cerebrolysin and who got the comparison, which limits bias.

Samples for NDEV determinations were obtained at baseline in the NDEV study and at baseline and study endpoint in the RCT.

Cognition and functioning were assessed at the same time points.

What Was Measured

The subject headings attached to it are Alzheimer Disease, Donepezil, Neurogranin, tau Proteins, Amyloid beta-Peptides, Cognitive Dysfunction and Biomarkers.

The authors tagged it with the keywords Aβ42, Cerebrolysin®, combination therapy and plasma neuronal-derived extracellular vesicles.

What This Means in Plain Language

The paper is a randomized study of Cerebrolysin in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Journal of Alzheimer's disease : JAD), a journal based in United States.

More context: the Cerebrolysin compound page, all human trials.